Johnson & Johnson and Procter & Gamble were among the companies hit with a flurry of class action lawsuits in New York, Florida and Louisiana federal courts over their sale of over-the-counter decongestants, following a finding by an FDA advisory panel that phenylephrine, an ingredient in many allergy and cold medicines, is ineffective as a nasal decongestant.
William “Bert” McBride, a shareholder at Trenam in Tampa, is a class action expert who is not involved in the lawsuits. He said litigators will be keeping their eyes on this case and those that could be filed in other jurisdictions.
To read the full article, click here.
